Skip to main
VKTX
VKTX logo

Viking Therapeutics (VKTX) Stock Forecast & Price Target

Viking Therapeutics (VKTX) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 55%
Buy 36%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Viking Therapeutics Inc. demonstrates a robust outlook due to its strategic advancements in biopharmaceutical development, particularly concerning its pipeline, which includes VK2809, VK5211, and VK0214, that target significant metabolic and endocrine disorders. The company has proactively secured large-scale production capacity and manufacturing agreements, enhancing its competitive positioning in the obesity treatment market, which is experiencing substantial growth. Additionally, the promising clinical trial results, including superior weight loss metrics compared to competitors, alongside potential therapeutic area market expansions, bolster the long-term value proposition for the firm.

Bears say

Viking Therapeutics Inc is facing a negative outlook primarily due to an expected increase in research and development expenses, which has led to a downward revision in financial projections. Concerns regarding negative safety or efficacy results from late-stage clinical trials pose significant risks, potentially resulting in further reductions to revenue forecasts and impacting market penetration for its drug candidates. Additionally, disappointing earnings results, including an earnings per share figure that fell below estimates, emphasize ongoing financial challenges and the uncertainties surrounding the progression of Viking's clinical programs.

Viking Therapeutics (VKTX) has been analyzed by 22 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 36% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viking Therapeutics (VKTX) Forecast

Analysts have given Viking Therapeutics (VKTX) a Buy based on their latest research and market trends.

According to 22 analysts, Viking Therapeutics (VKTX) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $70.09, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $70.09, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viking Therapeutics (VKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.